Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East.
Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East.
复制标题
DOI：
10.1038/s41409-021-01312-y
复制
发表时间：
2021-09
影响因子：
4.8
通讯作者：
Aljurf M
中科院分区：
文献类型：
--
作者：
El Fakih R;Haroon A;Alfraih F;Al-Khabori MK;Alzahrani M;Alhuraiji A;Hamadah A;AlJohani NI;Alahmari B;Essa MF;Motabi IH;Tailor IK;Almaghrabi RS;Al-Farsi K;Abosoudah I;Ayas M;Elhassan TA;Suhebeh AM;Ahmed SO;Alhayli S;Kaloyannidis P;Alsaeed A;Anezi KA;Alamoudi S;Damlaj M;Hashmi HA;Aljurf M
由SARS冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）是一种潜在的致命感染。癌症患者，特别是造血细胞移植（HCT）接受者严重免疫功能低下，可能处于这种感染的复杂过程的较高风险。我们旨在研究HCT后患者的COVID-19结局和严重程度。我们回顾性分析了2020年3月15日至2020年12月1日期间在中东10个移植中心诊断为COVID-19的HCT后患者。我们在10个移植中心确定了91名确诊为SARS-CoV-2感染的患者。出现COVID-19时的中位年龄为35岁。52例患者为allo-HCT后，其余39例患者为auto-HCT后。移植后的中位时间为14.9个月。死亡率为4.4%。住院率为53%。ICU入住率为14%。机械通气率10%。吸氧率为18%。从HCT到COVID-19的时间>6个月与较低的入院率和较低的“严重程度”复合终点率相关。67%的可评价患者出现抗体应答。在这一系列HCT接受者中，我们报告了COVID-19患者的总体良好临床结局，并提供了对该特定人群中该疾病临床病程的初步见解。
The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. The median age upon presentation with COVID-19 was 35. Fifty two patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 >6 months was associated with lower admission rates and lower rates of the “severity” composite endpoint. Antibody responses was seen 67% of evaluable patients. In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.1
作者：
Bhatti, Jasvinder Singh;Bhatti, Gurjit Kaur;Reddy, P. Hemachandra
通讯作者：
Reddy, P. Hemachandra
影响因子：
24.3
作者：
Guan, Wei-jie;Liang, Wen-hua;He, Jian-xing
通讯作者：
He, Jian-xing
影响因子：
28.2
作者：
Dai, Mengyuan;Liu, Dianbo;Cai, Hongbing
通讯作者：
Cai, Hongbing
影响因子：
6.2
作者：
Ali Malekhosseini, Seyed;Nikoupour, Hamed;Nikeghbalian, Saman
通讯作者：
Nikeghbalian, Saman